Tricyclic compound as IRAK4 inhibitor

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient, wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.

The invention claimed is: 
     
       1. A compound represented by the following Chemical Formula 1: 
       
         
           
           
               
               
           
         
         wherein, 
         A 1  is CH, 
         A 2  is N, 
         A 3  is CR 1 , 
         R 1  is hydrogen, a halogen, —COOR 5 , 
         R 2  is hydrogen, an amino group, —COOR 6 , 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         R 3  is hydrogen or a (C6-C12) aryl, 
         R 4  is -L 1 -L 2 -R 7 , 
         an amino group (—NH 2 ), a (C1-C12) heteroaryl or a (C6-C12) aryl of R 2  is optionally substituted with at least one or more groups selected from the group consisting of a (C1-C4) alkyl, a (C1-C4) alkyl substituted with a halogen, a (C1-C4) thioalkyl, an amino group (—NH 2 ), a methylamino group (—NHCH 3 ), a dimethylamino group (—N(CH 3 ) 2 ), —CH 2 OH, a (C1-C4) alkoxy, a hydroxyl group (—OH), a halogen, a methanesulfonyl group (—SO 2 CH 3 ), —SO 2 N(CH 3 ) 2 , a nitro group (—NO 2 ), a cyano group (—CN), 
       
       
         
           
           
               
               
           
         
         a (C6-C12) aryl of R 3  is optionally substituted with a nitro group (—NO 2 ), 
         L 1  is —N(R 8 )— or —O—, 
         L 2  is —(CH 2 ) m —, 
       
       
         
           
           
               
               
           
         
       
       and m is an integer from 2 to 5,
 R 7  is —N(R 9 ) 2 , —OR 10 , —SO 2 CH 3 , —SO 2 N(CH 3 ) 2 , or a monocyclic 5- to 7-membered saturated heterocycle, wherein the heterocycle comprises 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, 
 R 5  is a (C1-C4) alkyl, 
 R 6  is a (C1-C4) alkyl, 
 R 8  is hydrogen or a (C1-C4), 
 R 9  is a (C1-C4) alkyl, 
 R 10  is a (C1-C4) alkyl, 
 a heterocycloalkyl amino of R 7  is optionally substituted with at least one or more groups selected from the group consisting of —SO 2 CH 3  and —COOC(CH 3 ) 3  (—Boc). 
 
     
     
       2. The compound of  claim 1 , wherein the (C6-C12) aryl or substituted (C6-C12) aryl, which is R 2  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
       3. The compound of  claim 1 , wherein R 4  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
       4. The compound of  claim 1 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
       5. A pharmaceutical composition comprising the compound according to  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       6. A health food composition comprising the compound according to  claim 1  and a food-acceptable carrier.